Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that cannot be removed by surgery or has spread, and it must have the KRAS G12D mutation.
- You must have tried standard treatment and it didn't work or you can't have it, or you choose not to.
- You must be able to swallow pills and not have any major stomach or bowel problems that affect how the drug is absorbed.
- You must have at least one tumor that can be measured on a CT or MRI scan.
- You must be in fairly good health, able to do most daily activities (ECOG score 0 or 1), and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLC1101, which targets a specific genetic change (KRAS G12D) in tumors. It is given along with other treatments to see if it is safe and effective for people with advanced cancer that has not responded to standard therapy.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.